Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Two-Drug combo outsmart a deadly leukemia?

NCT ID NCT07008638

Recruiting now ⭐️ CURE ⭐️ Sponsor: Masonic Cancer Center, University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial is testing whether adding bortezomib to standard chemotherapy (CPX-351) can improve outcomes for people with a newly diagnosed, aggressive form of acute myeloid leukemia that has a TP53 mutation. The study aims to find a safe dose and see if the combination leads to more complete remissions. Participants will receive both drugs intravenously over several days in a hospital setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
bortezomib combined with CPX-351 (liposomal daunorubicin and cytarabine)
What this could lead to
If successful, this combination could offer a more effective treatment option for a hard-to-treat leukemia, potentially leading to higher remission rates and longer survival.
What could go wrong
This is an early-phase trial with a small number of participants, so the benefits are not yet proven. The combination may cause significant side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA TP53

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Masonic Cancer Center

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.